HITS: Force for Activation

On March 20, 2019, Posted by , In News, By , , With Comments Off on HITS: Force for Activation

 Tumor invasion and metastasis are major problems in the therapy of cancer patients. A team of researchers at the Heidelberg Institute of Theoretical Studies (HITS), the LMU Munich (both Germany) and the CNIO Madrid, Spain, has now elucidated the activation conditions for a key enzyme in this process – a…

HITS: Metabolic signaling as new concept for breast cancer risk estimation

On March 6, 2019, Posted by , In News, By , With Comments Off on HITS: Metabolic signaling as new concept for breast cancer risk estimation

HITS is partner of the international research consortium “MESI-STRAT” that explores the interplay of breast cancer metabolism and oncogenic signaling by systems medicine. The consortium was awarded by the European Union €6 million for five years. The main goal of the five-years project is to develop new models for knowledge-based…

DKFZ: Protein content as a marker for response to therapy in brain cancer

On March 6, 2019, Posted by , In News, By , , With Comments Off on DKFZ: Protein content as a marker for response to therapy in brain cancer

Brain tumors vary widely in how they respond to treatment. However, early assessment of therapy response is essential in order to choose the best possible treatment for the patient. Scientists from the German Cancer Research Center (DKFZ) have now been able to show in a study using non-invasive high-resolution 7-Tesla…

Researchers at Heidelberg University Hospital Develop First Marketable Blood Test for Breast Cancer

On February 25, 2019, Posted by , In News, By , With Comments Off on Researchers at Heidelberg University Hospital Develop First Marketable Blood Test for Breast Cancer

Diagnosis based on a combination of biomarkers / Gentle procedure for patients / Test provides further data on the tumour / CE certification started / Market launch by HeiScreen GmbH planned for this year / Cohort studies at Heidelberg University Hospital provide the basis Prof. Dr. Sarah Schott and Prof….

Official start of a new research center for individualized cancer immunotherapy: the Helmholtz Institute for Translational Oncology (HI-TRON)

On February 19, 2019, Posted by , In News, By ,, , With Comments Off on Official start of a new research center for individualized cancer immunotherapy: the Helmholtz Institute for Translational Oncology (HI-TRON)

The new Helmholtz Institute for Translational Oncology (HI-TRON Mainz) aims to develop into one of the world’s leading centres for personalised cancer immunotherapy. This is the ambitious goal of the cooperation partners German Cancer Research Center (DKFZ) and Research Institute for Translational Oncology (TRON gGmbH) at the Johannes Gutenberg University…

DKFZ – ERC grant for Stefan Pfister: “We must further advance pediatric cancer research”

On January 29, 2019, Posted by , In News, By , , With Comments Off on DKFZ – ERC grant for Stefan Pfister: “We must further advance pediatric cancer research”

KiTZ director Stefan Pfister, professor of pediatric neurooncology at the German Cancer Research Center (DKFZ) and the Heidelberg University Hospital, succeeded in gaining one of the prestigious ERC Consolidator Grants for his project entitled “BRAIN-MATCH”. The goal of BRAIN-MATCH is to characterize normal brain development using molecular-biological methods and to…

NEC provides a digital scanner to the Heidelberg University Hospital to accelerate joint research on cancer treatment

On January 28, 2019, Posted by , In News, By , , With Comments Off on NEC provides a digital scanner to the Heidelberg University Hospital to accelerate joint research on cancer treatment

NEC Laboratories Europe GmbH (NEC) provided a very high-resolution digital scanner to the Department of Applied Tumor Biology at the Institute of Pathology of the Heidelberg University Hospital for digitizing images of cancer tissue samples. The Heidelberg scientists Prof. Dr. Magnus of Knebel Doeberitz and Dr. Matthias Kloor with Motoo…

DKFZ: A major step towards digital oncology

On January 24, 2019, Posted by , In News, By , , With Comments Off on DKFZ: A major step towards digital oncology

Methods of artificial intelligence (AI) such as deep learning using neural networks are gaining increasing importance in health research and personalized medicine. In oncology, new experimental and diagnostic methods such as genome sequencing and whole-body imaging by magnetic resonance imaging are also generating growing amounts of data. © Fotolia Using…

DKFZ-Vaccination as a therapy: Experimental vaccine against cervical cancer successfully tested in mice

On January 23, 2019, Posted by , In News, By , , With Comments Off on DKFZ-Vaccination as a therapy: Experimental vaccine against cervical cancer successfully tested in mice

Scientists from the German Cancer Research Center (DKFZ) have developed an experimental vaccine to fight cervical cancer caused by human papillomaviruses (HPV). This has already been accomplished successfully in mice. Tumors regressed in half of the vaccinated animals. The scientists’ goal is to develop a therapeutic vaccine for people who…

VAXIMM Initiates Phase I/II Trial with VXM01 Oral T-cell Immunotherapy in Combination with PD-L1 Inhibitor Avelumab in Glioblastoma

On December 14, 2018, Posted by , In News, By , With Comments Off on VAXIMM Initiates Phase I/II Trial with VXM01 Oral T-cell Immunotherapy in Combination with PD-L1 Inhibitor Avelumab in Glioblastoma

VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the first patient has been dosed in a Phase I/II trial evaluating VXM01 oral immunotherapy in combination with avelumab*, a human anti-PD-L1 antibody, for the treatment of glioblastoma. The trial is part of a collaboration…